BioCina Merges to Form Global CDMO Leader
Deal News | Jan 13, 2025 | PR Newswire Cision BioCina
BioCina and NovaCina have announced a strategic merger that significantly impacts the global Contract Development and Manufacturing Organization (CDMO) sector. This merger combines the capabilities of both companies under the BioCina name, offering a seamless end-to-end service for biopharmaceutical and small molecule contract manufacturing. With operational bases in Adelaide and Perth, this merger positions BioCina to address high demand for integrated manufacturing solutions across multiple global markets. Mark W. Womack will remain at the helm as CEO, ensuring the continuation of client-focused and reliable operations. BioCina benefits from Australia's attractive tax incentives, and the company has an impeccable regulatory track record with approvals from major international entities like the US FDA and EMA.
Sectors
- Biopharmaceuticals
- Contract Manufacturing
Geography
- Australia – The merged entity maintains operations in Adelaide, South Australia, and Perth, Western Australia, and benefits from local tax incentives.
- Global – BioCina serves clients across North America, South America, Europe, Asia, and Africa, indicating a global market presence.
Industry
- Biopharmaceuticals – The merger involves companies specializing in the biopharmaceutical industry, focusing on the development and manufacturing of drug substances and products.
- Contract Manufacturing – BioCina and NovaCina operate as Contract Development and Manufacturing Organizations (CDMOs), offering services for cell line and process development, among others.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| BioCina | Target company and merged entity | Company | A global CDMO offering comprehensive manufacturing solutions across various biopharmaceutical and small molecule modalities. |
| NovaCina | Merging company | Company | Part of the merger with BioCina, bringing expertise in sterile fill-finish manufacturing. |
| Mark W. Womack | CEO | People | The CEO of BioCina, known for leading growth and maintaining a client-focused culture. |
| Masood Tayebi | CEO of Bridgewest Group | People | The Co-Founder and CEO of Bridgewest Group, the parent company of both BioCina and NovaCina. |
| Bridgewest Group | Parent company | Company | The parent company of BioCina and NovaCina, backing the merger. |